Navigation path

Additional tools

    Profile of registrant

Amgen Inc

Identification number in the register: 42243575237-50
Registration date: 07/02/2011 10:04:51

The information on this entity was last modified on: 17/04/2015 15:14:02
The date of the last annual update was: 17/04/2015 15:14:02
Next update due latest on: 17/04/2016

    Registrant : Organisation or self-employed individual

Amgen Inc


    Section of registration

II - In-house lobbyists and trade/business/professional associations

Companies & groups

    Contact details

One Amgen Center Drive
Thousand Oaks, California 91320-1799

(+1) 8054471000

Avenue Ariane, 5
Brussels 1200

(+32) 27752711

    Person with legal responsibility

Mr  Robert Bradway

Chairman and Chief Executive Officer

    Person in charge of EU relations

Mr  Douglas Gregory

Executive Director European Government Affairs

    Goals / remit

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.


    Specific activities covered by the Register

Engage governments and policy makers worldwide on issues important to Amgen to:

Ensure patients have access to medicines they need
Provide coverage and reimbursement that reward innovation
Introduce sound, science-based regulation
Enable biotechnology research and development (R&D)







    Number of persons involved in the activities described in the box above

100%: 1   75%: 2   50%: 3   25%: 3



Following the Transparency Register implementing guidelines, released on 21 January 2015, Amgen has reviewed its financial data regarding activities under the scope of Article 7 of the Inter-Institutional Agreement published in the official journal of 19 September 2014.

The estimated annual costs arising from activities covered by the Register cover direct and indirect lobbying.

Amgen calculated our total costs (as per the TR guidelines) by adding up the following elements:
1. Staff costs: based on the full-time equivalents (FTEs) already declared.
2. Office and administrative expenses: rent and utilities, supplies and materials.
3. In-house operational expenditure: cost of advocacy, PR or public affairs campaigns, marketing and advertising, use of media, organisation of events, publications, etc.
4. Representation costs: expenses incurred through taking part in events and meetings.
5. Outsourced activity costs: fees for consultants and subcontractors.
6. Membership and related fees: fees for joining relevant networks and structures.
7. Other relevant costs

This new estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Douglas GREGORY 23/01/2015 20/01/2016
Janusz LINKOWSKI 05/09/2015 03/09/2016
Marie Helene FANDEL 16/09/2015 14/09/2016
Joana Maria GANDARA LEITAO PAIVA 23/01/2015 20/01/2016

    Fields of interest

  • Budget
  • Competition
  • Consumer Affairs
  • Customs
  • Economic and Financial Affairs
  • Education
  • Employment and Social Affairs
  • Enlargement
  • Enterprise
  • Environment
  • External Relations
  • General and Institutional Affairs
  • Information Society
  • Internal Market
  • Justice and Fundamental Rights
  • Public Health
  • Research and Technology
  • Taxation
  • Trade

    Membership and affiliation

Amgen is a member of the following organizations in Brussels:
Ad Hoc Council
American Chamber of Commerce to the EU
EBE – European Biopharmaceutical Enterprises
EFPIA – European Federation of Pharmaceutical Industries and Associations
European Policy Centre
Transatlantic Policy Network

    Financial data

01/2014  -  12/2014

1,250,000 € - 1,499,999 €

0 €

not applicable

11,000 €

Research Framework Programme number 7: Kidney Connect 2013

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.